Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Tanya Gupta, MD, highlights the utility of adjuvant CDK4/6 and PARP inhibitors in patients with HR-positive, HER2-negative breast cancer.

Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer

Ocular adverse effects stemming from mirvetuximab soravtansine did not significantly affect HRQOL in FRα-positive platinum-resistant ovarian cancer.

Ocular AEs From Mirvetuximab Soravtansine Do Not Impact HRQOL in FRα+ Platinum-Resistant Ovarian Cancer

Treatment with abemaciclib plus hormonal therapy showed promise in LGSOC/EEC but not in HGSOC, and larger studies are needed to validate these findings.

Abemaciclib/Hormonal Therapy Combo Yields Clinical Activity in LGSOC/EEC

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Dr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

Interactive Tools

Biomarker Consortium

Subscribe

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Tsewang Tashi, MD, discusses the efficacy and tolerability of targeted therapies like avapritinib for patients with indolent systemic mastocytosis.

Avapritinib Leads a Charge of Novel Targeted Therapies for Indolent Systemic Mastocytosis

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Grzegorz S. Nowakowski, MD, discusses the FDA approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.

Brentuximab Vedotin Combo Adds Another Targeted Option Beyond CD19/CD20 in R/R LBCL

FDA Approves Pembrolizumab Plus Trastuzumab/Chemo for PD-L1+, HER2+ Gastric/GEJ Adenocarcinoma

 team as an assistant editor in 2025 after previously working on the 

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

1rem

primary

View

Recent Advances in Molecular Biomarkers in Multiple Myeloma

Medical Content

Videos

Dr Shaji Kumar and Dr Jonathan Kaufman discuss the evolving role of biomarkers in multiple myeloma.

Jonathan Kaufman, MD, provides an overview of multiple myeloma (MM) and reviews current biomarkers and molecular pathways commonly seen in MM.

Biomarkers in Multiple Myeloma (MM): Overview

Dr Shaji Kumar explains the role of t(11;14) translocation in patients with multiple myeloma and discusses treatment options for this specific population.

Role of t(11;14) Translocation in Patients with MM

Drs Shaji Kumar and Jonathan Kaufman review the BELLINI trial, as well as provide an overview of other investigational studies of BCL2 inhibitors for the treatment of patients with t(11;14) translocation with relapsed refractory multiple myeloma.

Evidence Around BCL2 Inhibitors for Patients with t(11;14) Translocation in MM

Shaji Kumar, MD, talks about new biomarkers that are being explored in patients with multiple myeloma.

Emerging Biomarkers in Multiple Myeloma

Two experts review strategies and barriers to overcome for biomarker testing in patients with multiple myeloma.

Testing for Biomarkers in Multiple Myeloma

Shaji Kumar, MD and Jonathan Kaufman, MD, discuss unmet needs in the multiple myeloma treatment landscape and share their insights on testing for biomarkers.

Future Perspectives in Biomarker Identification and Testing in MM

OncLive Insights

Role of t(11;14) Translocation in Patients with MM

EP: 1.Biomarkers in Multiple Myeloma (MM): Overview

EP: 2.Role of t(11;14) Translocation in Patients with MM

EP: 3.Evidence Around BCL2 Inhibitors for Patients with t(11;14) Translocation in MM

EP: 4.Emerging Biomarkers in Multiple Myeloma

EP: 5.Testing for Biomarkers in Multiple Myeloma

EP: 6.Future Perspectives in Biomarker Identification and Testing in MM

Newsletter